Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01077154 · ClinicalTrials.gov registry record · Phase 3
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
A Phase 3 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4,509
- Enrollment target
NCT01077154 is a Phase 3 study that was terminated before completion, run by Amgen. The registered enrollment target is 4,509 participants.
The verdict
NCT01077154, a Phase 3 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4,509 participants
- Enrollment target
Study Summary
This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast cancer, who are at high risk of disease recurrence.
Interventions
- DRUG Placebo
- DRUG Denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,509 participants |
| Start Date | 2010-06-02 |
| Est. Completion | 2018-03-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01077154
The ClinicalTrials.gov registry entry for NCT01077154 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4,509 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01077154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01077154 about?
NCT01077154 is a clinical study titled "Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)". This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast cancer, who are at high risk of disease recurrence.
What is the current status of trial NCT01077154?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4,509 participants. The study started on 2010-06-02. Estimated completion is 2018-03-26.
What interventions are being tested in trial NCT01077154?
The interventions under investigation include: Placebo (DRUG), Denosumab (DRUG).
Who is sponsoring clinical trial NCT01077154?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.